Webinars and Videos
[WEBINAR] Whole-Cell In Vitro Models Can Predict Clinically-Relevant Herb-Drug Interactions
Listen to our webinar with Dr. Amy Roe, Senior Toxicologist from The Procter and Gamble Company as she discusses a novel in vitro method to investigate HDIs using sandwich-cultured human hepatocytes (SCHH) that incorporated clearance and treated, the complex herbal mixture as a single entity.
[WEBINAR] Mechanistic Modeling Revealed the Induction of Hepatic Transporters and Altered Bile Acid Disposition: Critical Factors in Drug Safety
Hear Dr. Cen Guo discuss the mechanistic modeling studies recently published in the Journal of Pharmacology and Experimental Therapeutics May 2018.
[WEBINAR] Development of a Genetically-defined 3D Lung Cancer Model for Functional and Efficacy Studies
Discover how to use 3D models with primary, genetically-defined cells to allow for better functional and efficacy studies.
[WEBINAR] Early Phase Drug Development and the FDA’s Predictive Toxicology Roadmap
Hear Dr. Dennis Bashaw, Former Director, Division of Clinical Pharmacology-3, FDA, give his expert opinion on the FDA’s Predictive Toxicology Roadmap.
[WEBINAR] The New FDA Draft Guidance on In Vitro DDI Studies: How Will It Impact You
Hear from Drs. Andrew Parkinson, XPD Consulting, and Ron Laethem, Qualyst, offer their expert opinion on how the Guidance has changed and how it will impact drug development strategies.
[WEBINAR] CYP450 Induction Studies: Benefits of an In Vitro Hepatic Model with Functioning Transporters
Drs. Jeffrey Edwards (Intercept Pharmaceuticals) and Andrew Parkinson (XPD Consulting) discuss CYP450 induction studies in a sandwich culture human hepatocyte model using Transporter Certified hepatocytes and how the model was used to predict induction potential of obeticholic acid (Ocaliva).
[WEBINAR] Multiplex IHC and Digital Image Analysis - Supporting Immuno-Oncology Research
An introduction to Multiplex IHC, with a focus on the integration of the Perkin Elmer Vectra Polaris system where you will learn about how the generation of high content data derived for complex diseases such as immuno-oncology, from small and/or limited research samples and clinical biopsies.